Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 17 April 2013 | By Alexander Gaffney, RAC,
A new draft legislative report issued by a member of the European Parliament's Committee on the Environment, Public Health and Food Safety (ENVI), Peter Liese, would make significant changes to the manner in which in vitro diagnostic products are regulated in the EU.
The proposal follows a landmark proposal issued on 15 April 2013 by another ENVI member, Dagmar Roth-Behrendt, which called for medical devices marketed in the EU to be subject to a premarket assessment system in which high-risk devices would need to undergo a full review, while devices of lesser risk would undergo an expedited assessment procedure overseen by notified bodies.
Through IVDs are technically a subset of medical devices, they differ in that their reagents and assays are most often chemically or biologically based, and are rarely in direct contact with a human subject, vastly minimizing the risk they pose.
Liese's proposal makes a number of proposed changes to the way in which IVDs are regulated in the EU relative to a proposal put forth by the European Commission (EC).
For example, the proposal would allow Member States of the EU to "decide whether to restrict the use of any specific type of IVD device in relation to aspects that are not covered" by existing regulation. The wording of that change is taken from the advanced therapy products regulation, Liese noted in his report.
"It is a long-standing policy of the EU that the question if to allow, prohibit or allow within limits of sensible ethical technologies such as pre-implantation genetic testing is subject to the principle of subsidiarity," he explained. "Member States that allow these kinds of tests should make sure that they comply with the standards of this regulation but member states that want to prohibit it according to the national ethical debate should continue to have this possibility."
IVD testing would also be subject to an assessment by an ethics committee, with Liese saying that "the role of the ethics committee needs to be strengthened."
"Compared to the proposal on clinical trials for medicinal products, the provisions on interventional clinical performance studies are very weak and imprecise," Liese continued. "Interventional clinical performance studies may include a very significant risk for the patient, for example if the specimen is collected by spinal tap. Therefore the provisions need to be specified."
Those new requirements will be closely modeled off of existing device ethics standards, including the principles of informed consent and protection of special populations such as children and the intellectually disabled. The proposal would also allow for inspections of clinical trials.
The proposal's impact is being met with considerably less consternation than Roth-Behrendt's proposal. "This proposal is much more balanced and thought out than the general medical devices proposal," wrote Erik Vollebregt, a founding partner at Axon Lawyers, an EU medical device legal firm. "I think it the care that the rapporteur took to keep the proposal SME friendly is to be applauded."
However, Vollebregt also took issue with the provisions "preoccupation with any and all genetic testing," which he called "overly burdensome."
In particular, the proposal would ban any genetic test from being used by a non-medical professional, citing concerns that improper handling of the tests and notification of the results could lead to consumers being misled or otherwise harmed.
The act would allow for a transition period before the requirements come into effect, which would be longer for small and medium-sized enterprises (SMEs). Liese did note his concerns regarding the availability of enough notified bodies to carry out the proposal, explaining that designations of testing authority would need to be done as quickly as possible to ensure that IVDs don't experience shortages.
The full proposal may be found here.
Tags: IVDs, Proposal, ENVI, Legislation, Latest News, EU, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.